期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
干扰素IFNL4对巨噬细胞系THP-1免疫应答的影响 被引量:1
1
作者 党引利 徐溪 +3 位作者 陈丽展 张瑶 白丹 吴朔 《现代生物医学进展》 CAS 2018年第11期2047-2051,共5页
目的:分析Interferon-lambda 4(IFNL4)表达与巨噬细胞免疫应答间的关系,探讨IFNL4调控免疫应答的信号机制,发掘IFNL4在免疫调理方面的潜在应用价值。方法:建立THP-1细胞培养及分化刺激体系,使用RT-PCR检测不同分化状态THP-1细胞IFNL4的... 目的:分析Interferon-lambda 4(IFNL4)表达与巨噬细胞免疫应答间的关系,探讨IFNL4调控免疫应答的信号机制,发掘IFNL4在免疫调理方面的潜在应用价值。方法:建立THP-1细胞培养及分化刺激体系,使用RT-PCR检测不同分化状态THP-1细胞IFNL4的表达水平,并在THP-1细胞中过表达IFNL4,检测IFNL4过表达对THP-1细胞分泌IL-12、TNF-α、IL-10和TGF-β等细胞因子及细胞迁移效率的影响。结果:THP-1细胞分化抑制IFNL4的表达,分化前比分化后IFNL4表达水平相对定量下降255.46倍,差异显著性P<0.001;M2极化巨噬细胞较M1细胞表达IFNL4因子水平升高14.69倍,显著性差异P=0.009;IFNL4过表达可抑制IL-12和TNF-α表达水平,其中TNF-α表达水平变化具有统计学意义(P=0.017),表达水下降5.97倍。IFNL4可促进IL-10和TGF-β的表达,其中TGF-β变化具有统计学意义(P=0.046),表达水平相对上升2.42倍。且IFNL4对THP-1细胞迁移效率具有抑制作用(P=0.005),刺激前细胞迁移数为45.33,IFNL4刺激后迁移数为32.67,迁移移效率下降1.39倍。结论:干扰素IFNL4在分化的M2型THP-1巨噬细胞中具有较高的表达水平,且对THP-1的免疫应答具有一定的抑制作用。 展开更多
关键词 ifnl4 THP-1巨噬细胞 免疫应答 细胞因子 巨噬细胞迁移
原文传递
IFNL4单核苷酸多态性与TDF+3TC+EFV抗病毒治疗应答的关联性 被引量:1
2
作者 丁亚 姚静 +2 位作者 彭小青 梁辉勇 苏齐鉴 《热带医学杂志》 CAS 2023年第2期154-157,163,共5页
目的探讨干扰素λ4(IFNL4)单核苷酸多态性(SNP)与替诺福韦(TDF)+拉米夫定(3TC)+依非韦伦(EFV)抗病毒治疗应答的相关性。方法选取2011年1月-2020年1月广西中医药大学附属瑞康医院门诊及住院确诊的HIV感染患者共137例,并予TDF+3TC+EFV抗... 目的探讨干扰素λ4(IFNL4)单核苷酸多态性(SNP)与替诺福韦(TDF)+拉米夫定(3TC)+依非韦伦(EFV)抗病毒治疗应答的相关性。方法选取2011年1月-2020年1月广西中医药大学附属瑞康医院门诊及住院确诊的HIV感染患者共137例,并予TDF+3TC+EFV抗病毒方案治疗12个月以上,定期门诊随访。对IFNL4的2个SNP位点进行基因分型,比较艾滋病患者抗病毒治疗12个月后基因分型之间的免疫应答和病毒应答情况。结果位点rs4803221-GC基因型占8.8%,CC基因型占91.2%,rs12971396-GC和CC基因型分别为97.8%和2.2%。IFNL4-rs4803221、rs12971396不同基因型的患者相比较,基线CD4^(+)、CD8^(+)T细胞计数、CD4^(+)/CD8^(+)T细胞比值差异均无统计学意义(t_(rs4803221)=0.074、-0.612、0.701,t_(rs12971396)=1.896、1.682、-0.568,P均>0.05)。抗病毒治疗12个月后,不同基因型之间有效免疫学应答比例或有效病毒应答比例的差异也无统计学意义(P>0.05)。结论广西地区艾滋病患者的IFNL4-rs4803221基因型主要为CC,IFNL4-rs12971396基因型主要为GC,其基因型与TDF+3TC+EFV抗病毒应答无关。 展开更多
关键词 HIV 干扰素λ4 单核苷酸多态性 基因型
原文传递
Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection 被引量:2
3
作者 Jan Sperl Sona Frankova +7 位作者 Renata Senkerikova Magdalena Neroldova Vaclav Hejda Miroslava Volfova Dusan Merta Ondrej Viklicky Julius Spicak Milan Jirsa 《World Journal of Gastroenterology》 SCIE CAS 2015年第18期5496-5504,共9页
AIM: To identify predictors of sustained virological response in hemodialysed patients treated by PEGinterferon α for chronic hepatitis C, genotype 1.METHODS: The sustained virological response(SVR) rate, IL28 B geno... AIM: To identify predictors of sustained virological response in hemodialysed patients treated by PEGinterferon α for chronic hepatitis C, genotype 1.METHODS: The sustained virological response(SVR) rate, IL28 B genotype, IFNL4 genotype, initial viral load(IVL) and other pretreatment variables in 39 endstage renal disease patients(ESRD) on maintenance haemodialysis(HD) infected with hepatitis C virus(HCV), genotype 1b, were compared with a control group of 109 patients with normal kidney function treated within the same period. All the patients were treatment nave and had well compensated liver disease. The ESRD patients received 135 μg of PEGylated interferon α-2a(Peg IFN-α) weekly and a reduced dose of ribavirin(RBV) was administered to 23/39 patients with an initial haemoglobin level > 10 g/d L. Control group patients were given standard doses of Peg IFN-α and RBV. SVR was assessed as HCV RNA negativity 24 wk post-treatment. A t-test or ANOVA were used for comparisons of the means and a χ2 testcompared the frequencies.Logistic regression was used to determine significant predictors of SVR.Cutoff values for continuous variables were obtained from Receiver Operating Characteristic analysis.RESULTS:The distribution of IL28B rs12979860 CC,CT and TT genotypes in the ESRD group was 28.2%,64.1%and 7.7%,respectively,and 19.3%,62.4%and18.3%in the controls.The IFNL4 genotype was in almost absolute linkage disequlibrium with IL28B.The proportion of patients with a low IVL(<600000 IU/m L)was significantly higher in the ESRD group than in the controls(28/39,71.8%vs 51/109,46.8%,P=0.009),as was the proportion of patients with low IVL in IL28B CC carriers compared with non-CC carriers in the ESRD group(10/11,90.9%vs 18/28,64.3%,P=0.0035).This difference was not found in the controls(7/22,31.8%vs 44/87,50.6%,P=0.9).The overall SVR rate was 64.1%(25/39)in the ESRD group and 50.5%(55/109)in the control group(P=0.19).11/11(100%)and 19/22(86.4%)IL28B CC patients achieved SVR in the ESRD and control groups,respectively.A statistically significant association between SVR and IL28B and IFNL4 variants was found in both groups.The ESRD patients who achieved SVR showed the lowest IVL[median 21000,interquartile range(IQR):6000-23000IU/m L],compared with ESRD individuals without SVR(1680000,IQR:481000-6880000,P=0.001),controls with SVR(387000,IQR:111000-1253000)and controls without SVR(905000,IQR:451000-3020000).In ESRD,an IVL<600000 IU/m L was strongly associated with SVR:24/28(85.7%)patients who achieved SVR had viraemia below this threshold.CONCLUSION:Haemodialysis decreases the viral load,especially in IL28B CC genotype carriers.A low IVL was the strongest predictor of SVR in ESRD patients identified in multivariate analysis. 展开更多
关键词 END-STAGE renal disease HEPATITIS C virus GENOTYPE 1 INTERFERON alpha ifnl4 RIBAVIRIN
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部